Botulinum toxin type B de novo therapy of cervical dystonia: Frequency of antibody induced therapy failure

Journal of Neurology

Volumn 252, Issue 8, 2005, Pages 904-907

  Dressler, D ^a   Bigalke, H ^b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antibody formation; Botulinum toxin type A; Botulinum toxin type B; De novo therapy; Electromyography; Therapy failure

Indexed keywords

ANTIBODY; BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ADULT; ANTIBODY PRODUCTION; ANTICHOLINERGIC EFFECT; ARTICLE; CLINICAL ARTICLE; DYSTONIA; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SIDE EFFECT; SPASMODIC TORTICOLLIS; TREATMENT FAILURE;

ADULT; BOTULINUM TOXINS; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; SEVERITY OF ILLNESS INDEX; TORTICOLLIS; TREATMENT FAILURE;

EID: 23944454472     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-005-0774-3     Document Type: Article

References (23)

1. Tsui JK, Eisen A, Mak E, Carruthers J, Scott A, Calne (1985) DBA pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 12:314-316
2. Jankovic J, Schwartz KS (1991) Clinical correlates of response to botulinum toxin injections. Arch Neurol 48:1253-1256
3. Anderson TJ, Rivest J, Stell R, Steiger MJ, Cohen H, Thompson PD, Marsden CD (1992) Botulinum toxin treatment of spasmodic torticollis. J R Soc Med 85:524-529
4. Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P (1993) Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 43:1715-1718
5. Greene PE, Fahn S (1994) Response to botulinum toxin F in seronegative botulinum toxin A-resistant patients. Mov Disord 11:181-184
6. Jankovic J, Schwartz K (1995) Response and immunoresistance to botulinum toxin injections. Neurology 45:1743-1746
7. Dressler D, Rothwell JC, Bigalke H (2000) The sternocleidomastoid test: an in-vivo assay to investigate botulinum toxin antibody formation in man. J Neurol 247:630-632
8. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, Trosch R, Singer C, Brin MF, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M (1999) Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 53:1439-1446
9. Dressler D, Benecke R, Bigalke H (2003) Botulinum toxin type B (Neuro-Bloc® in patients with botulinum toxin type A antibody-induced therapy failure. J Neurol 250:967-969
10. Consky ES, Basinski A, Belle L, Ranawaya R, Lang AE (1990) The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability. Neurology 40(Suppl 1):445
11. Dressler D, Lange M, Bigalke H (2004) Detecting neutralising antibodies against botulinum toxin type B with a mouse diaphragm assay. Mov Disord 19(Suppl 9):S105
12. Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp Neurol 147:96-102
13. Dressler D, Benecke R (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 49:34-38
14. Dressler D (1997) Botulinum toxin therapy failure: causes, evaluation procedures and management strategies. Eur J Neurol 4(Suppl 2):S67-S70
15. Kessler KR, Skutta M, Benecke R (1999) Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 246:265-274
16. Jankovic J, Ahsan J, Vuong KD (2002) Comparison of immunogenicity of old versus current BOTOX in cervical dystonia. Naunyn Schmiedebergs Arch Pharmacol 365(Suppl 2):R25
17. Setler P (2000) The biochemistry of botulinum toxin type B Neurology 55(Suppl 5):S22-S28
18. Health and Human Services, Public Health Service, Food and Drug Administration, Center for Biologics Evaluation and Research, Division of Clinical Trial Design and Analysis (2000) MyoBloc: Summary Basis of Approval Cervical Dystonia. Supplemental Clinical Review. Available from US Government through Freedom of Information (http://www.fda.gov/cder/biologics/products/ botelan12800.htm)
19. Dressler D (2000) Complete secondary botulinum toxin therapy failure in blepharospasm. J Neurol 247:809-810
20. Dressler D (2004) New formulation of BOTOX®: Complete antibody-induced therapy failure in hemifacial spasm. J Neurol 251:360
21. Dressler D, Dirnberger G (2000) Botulinum toxin therapy: Risk factors for therapy failure. Mov Disord 15(Suppl 2):51
22. Dressler D (2002) Clinical features of secondary failure of botulinum toxin therapy. Eur Neurol 48:26-29
23. Dressler D, Muenchau A, Bhatia KP, Quinn NP, Bigalke H (2002) Antibody induced botulinum toxin therapy failure: Can it be overcome by increased botulinum toxin doses? Eur Neurol 47:118-121